MCSAID vs VISPro
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
MCSAID
Read full descriptionHide full description
MCSAID is an educational application dedicated to the topic of mechanical cardiocirculatory support for patients with cardiogenic shock. A basic section introduces the definitions and classifications of cardiogenic shock as well as some of the common devices used for hemodynamic support in unstable patients. There is an algorithm for helping understand the decision process depending on key clinical variables such as cardiac output and PAPI. There are also several weaning and escalation algorithm. A calculator section is available for some common hemodynamic variables used in MCS decision-making and is available for quick-reference throughout the algorithm. MCSAID is an educational application for medical professionals and is not intended for making medical diagnoses. Medical decisions must be made by licensed professionals with the entire context of a patient’s medical history. If you are seeking a medical diagnosis, contact your physician and if you are experiencing a medical emergency, call your local emergency medical services.
VISPro
Read full descriptionHide full description
VISPro is a clinical calculator for the Vasoactive-Inotropic Score (VIS) and Norepinephrine Equivalent (NEE), designed for ICU, cardiac, and critical care teams. CALCULATE VIS AND NEE IN SECONDS Enter patient weight and vasoactive drug doses (mcg/kg/min or units/kg/min). VIS and NEE update in real time. Supported drugs include dopamine, dobutamine, epinephrine, milrinone, vasopressin, norepinephrine, and phenylephrine—with formulas aligned to published standards (Gaies et al., NEE literature). RISK STRATIFICATION AND MORTALITY CONTEXT See risk level (Low / Moderate / High / Very High) and evidence-based mortality estimates at a glance. Ranges are informed by pooled surgical and ICU data so you can quickly contextualize support level and discuss prognosis. TRACK TRENDS OVER TIME Save scores by patient and view VIS and NEE over time. Switch between VIS and NEE on the trend chart, review risk and mortality for each entry, and export or share a concise score report. BUILT FOR CLINICIANS • Clean, fast interface—no account required for calculation • Per-drug VIS and NEE contributions • Optional NEE calculator with same drug set • References to key literature (Gaies 2014, VIS meta-analyses, NEE sources) • Dark mode support • iPhone and iPad For clinical use at the bedside or in rounds. Not a substitute for clinical judgment or institutional protocol.
Screenshots
Verdict
The clearest difference is price: MCSAID at Free against VISPro's $0.99. MCSAID also leads on iOS requirement (15.0 vs 17.0). VISPro's advantage is update cadence (every 2 weeks vs every 40 months) and chart position (#195 vs unranked). On ads, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
MCSAID is free to download; VISPro costs $0.99 up front. Neither carries in-app purchases, so what you see is what you pay.
MCSAID ships an update every 40 months, VISPro every 2 weeks. The most recent releases landed on October 16, 2026 and October 25, 2026 respectively.
| Parameter | MCSAID | VISPro |
|---|---|---|
| Price | Free — better | $0.99 |
| Update frequency | Every 40 months | Every 2 weeks — better |
| Ads | No | No |
| In-app purchases | No | No |
| Best chart rank | — | #195 — better |
| Devices | iPhone, iPod | iPhone, iPad |
| Requires iOS | 15.0 — better | 17.0 |
| Further details — not scored | ||
| Size | 46 MB | 2 MB |
| Age rating | 17+ | 17+ |
| Developer | Cardiology Apps LLC | Readfeed, Inc. |
In-app purchases
MCSAID
No in-app purchases
VISPro
No in-app purchases









